DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Injury Research Grant Review Committee: Conference Call Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following conference call committee meeting.

Name: Injury Research Grant Review Committee (IRGRC).

Time and Date: 1:30 p.m.–3:30 p.m., February 24, 1999.

Place: National Center for Injury Prevention and Control (NCIPC), CDC, Koger Center, Vanderbilt Building, 1st Floor, Conference Room 1006, 2939 Flowers Road, South, Atlanta, Georgia 30341. (Exit Chamblee-Tucker Road off I–85.)

Status: Open: 1:30 p.m.–1:45 p.m., February 24, 1999. Closed: 1:45 p.m.–3:30 p.m., February 24, 1999.

Purpose: This committee is charged with advising the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the scientific merit and technical feasibility of grant applications received from academic institutions and other public and private profit and nonprofit organizations, including State and local government agencies, to conduct specific injury research that focus on prevention and control and to support injury prevention research centers.

Matters to be Discussed: Agenda items include announcements; discussion of review procedures; future meeting dates; and review of grant applications.

Beginning at 1:45 p.m., through 3:30 p.m., February 24, the Committee will meet to conduct a review of grant applications. This portion of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92–463.

Agenda items are subject to change as priorities dictate.

Contact Person For More Information: John F. Finklea, M.D., Acting Executive Secretary, IRGRC, NCIPC, CDC, 4770 Buford Highway, NE, M/S K58, Atlanta, Georgia 30341–3724. Telephone 770/488–4330.

The Director, Management Analysis and Services office has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.


John L. Williams,
Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99–2905 Filed 2–5–99; 8:45 am]
BILLING CODE 4160–18–U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Child Welfare Demonstrations Pursuant to Section 1130 of the Social Security Act (the Act); Parts B and E of title IV of the Act; Public Law 103–432 and Public Law 105–89

AGENCY: Administration on Children, Youth and Families, ACF, DHHS.

ACTION: Public notice.

SUMMARY: This public notice announces that the Department of Health and Human Services (Department) is seeking proposals on child welfare demonstration projects and has published Information Memorandum ACYF–CB–IM–99–03 dated 1–21–99, January 21, 1999, entitled Child Welfare Demonstration Projects. This memorandum informs interested parties of: (1) The principles, goals and objectives the Department will consider in exercising its discretion to approve or disapprove demonstration projects which would require waivers of certain sections of the Act under the authority in section 1130 (b) of Part A of title XI of the Social Security Act (the Act), added by Pub. L. 103–432 and amended by Pub. L. 105–89; (2) the procedures the Department expects the States to employ in involving the public in the development of proposed demonstration projects under section 1130; and (3) the procedures the Department will follow in receiving and reviewing the demonstration proposals.

The Information Memorandum: (1) Contains guidelines and procedures for submitting a proposal; and (2) identifies limitations on demonstration projects and provisions of titles IV–B and IV–E of the Act that are not subject to waiver.

The Department will give preference to proposals that test policy and service program alternatives that are unique in their approach to serving children and families, that differ significantly from other approved child welfare demonstrations, and that are from States that have not previously been approved for a Child Welfare Demonstration project. The Department will give first consideration to proposals that reflect the topical priorities outlined in Appendix I of the Information Memorandum.

FOR FURTHER INFORMATION CONTACT: Copies of the Information Memorandum containing the guidelines, and topical priorities can be found at the ACF Website at: http://www.acf.dhhs.gov/programs/cb/demonstrations or may be obtained from the National Clearinghouse on Child Abuse and Neglect Information, 330 C Street, SW, Washington, DC 20447, (800) 394–3366, INTERNET address: ncanch@calib.com. For further information, contact the Children’s Bureau, Administration on Children, Youth and Families, DHHS at (202) 205–8618.

DATES: Proposals for a Child Welfare Demonstration project will be accepted at any time. States that are interested in a project to be considered for approval in fiscal year 1999 are strongly encouraged to submit a Letter of Intent before April 5, 1999.

ADDRESSES: All Letters of Intent and complete proposals should be submitted to Laura Oliven, Children’s Bureau, Administration on Children, Youth and Families, 330 C Street, SW, Room 2068, Washington, DC 20447. Facsimile transmission of a Letter of Intent ONLY will be accepted providing it is followed by an original copy. The FAX number is (202) 260–9345.

SUPPLEMENTARY INFORMATION: This announcement and the Information Memorandum Number ACYF–CB–IM–99–03 do not create any right or benefit, substantive or procedural, enforceable at law or equity, by any person, or entity, against the United States, its agencies or instrumentalities, the States, or any other person.
DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

**Docket No. 99F--0817**

**Monsanto Co.: Filing of Food Additive Petition**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that Monsanto Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of L-phenylalanine, N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-1-methyl ester as a general use sweetener. Monsanto proposes that this additive be identified as neotame.

**DATES:** Written comments on the petitioner's environmental assessment by April 10, 1999.

**ADDRESS:** Submit written comments on the Dockets Management Branch (HFA--305), Food and Drug Administration, 5630 Fishers Lane, Rockville, MD 20857.

**FURTHER INFORMATION CONTACT:** Blondell Anderson, Center for Food Safety and Applied Nutrition (HFS--206), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202--418--3106.

**SUPPLEMENTARY INFORMATION:** Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 9A4643) has been filed by Monsanto Co., 5200 Old Orchard Rd., Skokie, IL 60077. The petition proposes to amend the food additive regulations in part 172 Food Additives Permitted for Direct Addition to Food for Human Consumption to provide for the safe use of N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine 1-methyl ester as a general use sweetener. Monsanto proposes the sweetener be identified as neotame. The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before April 10, 1999, submit comments to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register.

**Dated:** January 28, 1999.

Laura M. Tarantino,
Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

**BILLING CODE 4160--01--F**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

**Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting is open to the public. Name of Committee: Endocrinologic and Metabolic Drugs Advisory Committee. General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues. Date and Time: The meeting will be held on March 26, 1999, 8 a.m. to 5 p.m. Location: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD. Contact Person: Kathleen R. Reddy or LaniSue S. Giles, Center for Drug Evaluation and Research (HFD--21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301--827--7001, or FDA Advisory Committee Information Line, 1--800--741--8138 (301--443--0572 in the Washington, DC area), code 12536. Please call the Information Line for up-to-date information on this meeting. Agenda: The committee will discuss experience since approval for marketing, benefits, and risks of Rezulin (troglitazone, Parke-Davis Pharmaceutical Research, a Division of Warner-Lambert) in the treatment of type 2 diabetes mellitus. Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by March 23, 1999. Oral presentations from the public will be scheduled between approximately 8:30 a.m. and 9:30 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 23, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. In addition, an open public session will be conducted after the scientific presentations. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: January 26, 1999.

Michael A. Friedman,
Deputy Commissioner for Operations.

**BILLING CODE 4160--01--F**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

**Draft Guidance for the Content of Premarket Notifications (510(k)'s) for Extracorporeal Shock Wave Lithotripters Indicated for the Fragmentation of Kidney and Ureteral Calculi; Availability**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of the draft guidance entitled "Guidance for the Content of